US 12,329,899 B2
Dry powder inhaler and methods of use
Kambiz Yadidi, Los Angeles, CA (US)
Assigned to ASPEYA US INC., Stamford, CT (US)
Filed by Aspeya US Inc., Stamford, CT (US)
Filed on Sep. 11, 2017, as Appl. No. 15/701,257.
Application 15/701,257 is a continuation of application No. 13/843,285, filed on Mar. 15, 2013, granted, now 9,757,529.
Application 13/843,285 is a continuation in part of application No. 13/791,734, filed on Mar. 8, 2013, granted, now 9,757,395.
Claims priority of provisional application 61/740,407, filed on Dec. 20, 2012.
Prior Publication US 2018/0064890 A1, Mar. 8, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. A61M 15/00 (2006.01); A61K 31/616 (2006.01)
CPC A61M 15/0045 (2013.01) [A61K 31/616 (2013.01); A61M 2202/064 (2013.01)] 22 Claims
OG exemplary drawing
 
1. A method of reducing a risk of a thromboembolic event in a patient in an emergency, the method comprising:
administering through oral inhalation to the patient a dose of a dry powder consisting essentially of acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof, and, optionally, at least one carrier, particles of the dry powder having a median geometric diameter in a range of from 1 μm to 5 μm,
wherein the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof in the dose is in a range of from 1 mg to less than 80 mg.